Combined versus standalone XEN45 Gel Stent implantation in either phakic or pseudophakic patients: a case-matched study

Purpose To determine differing outcomes among either phakic or pseudophakic patients who received standalone XEN45 Gel Stent (Allergan, an AbbVie Company, CA, USA) implantation and patients who underwent combined surgery with phacoemulsification. Methods This retrospective single-center study involv...

Full description

Saved in:
Bibliographic Details
Published in:Graefe's archive for clinical and experimental ophthalmology 2024-04, Vol.262 (4), p.1253-1262
Main Authors: Kiessling, David, Rennings, Corinna, Hild, Matthias, Lappas, Alexandra, Dietlein, Thomas Stefan, Roessler, Gernot Franz, Widder, Randolf Alexander
Format: Article
Language:English
Subjects:
Comparative analysis
Glaucoma
Glaucoma Drainage Implants
Glaucoma, Open-Angle
Humans
Implants
Intraocular Pressure
Latency
Medicine
Medicine & Public Health
Ophthalmology
Patients
Retrospective Studies
Stents
Surgery
Surgical outcomes
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To determine differing outcomes among either phakic or pseudophakic patients who received standalone XEN45 Gel Stent (Allergan, an AbbVie Company, CA, USA) implantation and patients who underwent combined surgery with phacoemulsification. Methods This retrospective single-center study involved 180 eyes of 180 participants who underwent XEN45 Gel Stent implantation, of which 60 eyes received combined surgery with phacoemulsification (combined group). Standalone stent implantation was performed on 60 phakic (phakic group) and on 60 pseudophakic eyes (pseudophakic group). The groups were matched in a ratio of 1:1:1 based on multiple criteria. Successful surgery was defined by three scores: IOP at the longest follow-up of 
ISSN:0721-832X
1435-702X
1435-702X
DOI:10.1007/s00417-023-06283-y